Iftikhar Ali Shah1, Mubeen Memon2, Sheeba Ansari3, Ratan Kumar4, Sultan A Chandio5, Shahid H Mirani6, Amber Rizwan7. 1. Internal Medicine, Ghulam Muhammad Mahar Medical College and Hospital, Sukkur, PAK. 2. Pulmonology, Liaquat University of Medical and Health Sciences, Jamshoro, PAK. 3. Internal Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK. 4. Internal Medicine, Civil Hospital Khairpur, Khairpur, PAK. 5. Medicine, Shaheed Mohtarma Benazir Bhutto Medical University Larkana, Larkana, PAK. 6. Surgery, Ghulam Muhammad Mahar Medical College, Sukkur, PAK. 7. Family Medicine, Jinnah Post Graduate Medical Center, Karachi, PAK.
Abstract
INTRODUCTION:Coenzyme Q10 (CoQ10) has a potential role in reducing the risk of myocardial infarction by slowing the progression of atherosclerosis and improving ischemia. In this study, we will assess the role of coenzyme Q10 in prophylaxis for reducing myocardial infarction and mortality related to myocardial infarction. METHODS: This open-label two open placebo-controlled randomized clinical trial was conducted in a tertiary care hospital in Sukkur, Pakistan from April 2016 to September 2019. Eight hundred nighty-two (892) patients with clinically diagnosed and documented evidence of hypertension were enrolled in the study from the outpatient department. Participants were randomized into two groups by 1:1 ratio using an online randomizer software, Research Randomizer (https://www.randomizer.org/). Group A received 100 mg coenzyme Q10 daily (coenzyme Q10 group) in addition to standard therapy and group B received standard therapy only (placebo group). RESULTS: Participants who received coenzyme Q10 had fewer incidence of non-fatal myocardial infarction over 12 months (5.4% vs 8.4%) with relative risk reduction of 2.92 (confidence interval 95%, 0.55-2.76). The number needed to treat to prevent one non-fatal myocardial infarction was 34. Participants who received coenzyme Q10 had fewer incidence of fatal myocardial infarction over 12 months (1.5% vs 3.1%) with relative risk reduction of 1.65 (confidence interval 95%, 0.39-3.69). Number needed to treat to prevent one fatal myocardial infarction was 60. CONCLUSION: According to this study, coenzyme Q10 reduced the incidence of fatal and non-fatal myocardial infarctions. Clinicians should consider adding coenzyme Q10 to the treatment regimen of high-risk patients of myocardial infarction. We suggest coenzyme Q10 may be an effective prophylactic agent in patients at risk of myocardial infarction and it may help in reducing burden on the health care system.
RCT Entities:
INTRODUCTION:Coenzyme Q10 (CoQ10) has a potential role in reducing the risk of myocardial infarction by slowing the progression of atherosclerosis and improving ischemia. In this study, we will assess the role of coenzyme Q10 in prophylaxis for reducing myocardial infarction and mortality related to myocardial infarction. METHODS: This open-label two open placebo-controlled randomized clinical trial was conducted in a tertiary care hospital in Sukkur, Pakistan from April 2016 to September 2019. Eight hundred nighty-two (892) patients with clinically diagnosed and documented evidence of hypertension were enrolled in the study from the outpatient department. Participants were randomized into two groups by 1:1 ratio using an online randomizer software, Research Randomizer (https://www.randomizer.org/). Group A received 100 mg coenzyme Q10 daily (coenzyme Q10 group) in addition to standard therapy and group B received standard therapy only (placebo group). RESULTS:Participants who received coenzyme Q10 had fewer incidence of non-fatal myocardial infarction over 12 months (5.4% vs 8.4%) with relative risk reduction of 2.92 (confidence interval 95%, 0.55-2.76). The number needed to treat to prevent one non-fatal myocardial infarction was 34. Participants who received coenzyme Q10 had fewer incidence of fatal myocardial infarction over 12 months (1.5% vs 3.1%) with relative risk reduction of 1.65 (confidence interval 95%, 0.39-3.69). Number needed to treat to prevent one fatal myocardial infarction was 60. CONCLUSION: According to this study, coenzyme Q10 reduced the incidence of fatal and non-fatal myocardial infarctions. Clinicians should consider adding coenzyme Q10 to the treatment regimen of high-risk patients of myocardial infarction. We suggest coenzyme Q10 may be an effective prophylactic agent in patients at risk of myocardial infarction and it may help in reducing burden on the health care system.
Authors: Samy M Eleawa; Mahmoud Alkhateeb; Sanjoy Ghosh; Fahaid Al-Hashem; Abdullah S Shatoor; Abdulmohsen Alhejaily; Mohammad A Khalil Journal: Int J Physiol Pathophysiol Pharmacol Date: 2015-03-20
Authors: Klaus K A Witte; Nikolay P Nikitin; Anita C Parker; Stephan von Haehling; Hans-Dieter Volk; Stefan D Anker; Andrew L Clark; John G F Cleland Journal: Eur Heart J Date: 2005-08-04 Impact factor: 29.983